ArticlePloS one2025
Deciphering insights into commercial Myrrh species authenticity from the psbA-trsnH genetic region.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on the anti-tumor effects of myrrh (Commiphora myrrha) and its bioactive constituents.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe genetic analysis, particularly focusing on the psbA-trnH region, aims to tackle the challenges linked to myrrh identification and improve quality control in medicinal and aromatic plant sectors. This process reveals the genetic diversity inherent in myrrh species, identifies adulterants, and assesses consistency with pharmacopoeia-designated species.
methodsA meticulous investigation was conducted, involving twenty-five myrrh samples sourced from diverse origins and one adulterant sample. The methodology encompassed precise execution of DNA extraction, PCR amplification targeting the psbA-trnH region, sequencing, and subsequent data analysis. Additionally, the integration of GenBank data was employed to enrich the genetic analysis.
resultsThe psbA-trnH region demonstrated 100% amplification efficiency across all myrrh samples, accurately identifying three distinct species-Commiphora gileadensis, Commiphora myrrha, and Commiphora edulis. Only 8% of samples aligned with pharmacopoeia-specified species, revealing a significant misalignment. The identified adulterant, Liquidambar formosana, underscored the efficacy of the genetic approach. Genetic distances and haplotype analysis offered insights into myrrh species diversity. Intraspecific and interspecific distances highlighted the discriminatory potential of the psbA-trnH region. A phylogenetic tree illustrated distinct genetic clusters among Commiphora species and Liquidambar formosana.
conclusionsIt affirms the robustness of the psbA-trnH region for authenticating myrrh and emphasizes the necessity of adapting pharmacopoeial standards to accurately mirror genetic diversity. An avenue for exploring therapeutic variations within myrrh species and advocates collaboration among researchers, regulatory agencies, and industry stakeholders to fortify comprehensive quality management measures within the context of agronomy-focused herbal products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.